Synthetic Minds | Pharma Companies Are Quietly Becoming Compute Companies
The Synthetic Minds newsletter offers short daily insights to get you thinking. If you enjoy it, please forward. If you need more insights, subscribe to Futurwise and get 25% off for the first three months!
I turned my book into an interactive masterclass, built entirely with AI. Read how I did it here, or start using it for free.
Today’s topic: Health
Pharma Companies Are Quietly Becoming Compute Companies
The company most likely to discover your next medicine may not have a single laboratory. It may have a data centre.
Roche deployed 2,176 NVIDIA GPUs on premises across the US and Europe in March, bringing its total to more than 3,500 Blackwell GPUs, the largest announced GPU footprint in the pharmaceutical industry.
The compute powers drug discovery, clinical diagnostics, and digital pathology.
At the same time, Eli Lilly committed $2.75 billion not to a molecule but to Insilico Medicine's Pharma.AI platform, the generative system that produced 28 drugs, nearly half in clinical trials.
In an interview published April 1, Insilico's CEO argued the commercial model has shifted from licensing individual drug candidates to licensing the platforms that generate them.
Three data points. One pattern. Pharmaceutical companies are becoming compute companies.
Roche is building GPU infrastructure at a scale that would have been associated with a Big Tech company five years ago. Lilly is buying access to AI systems, not chemical compounds. Insilico is positioning its platform, not its pipeline, as the product.
The competitive moat in drug development is migrating from lab expertise and clinical trial networks to data infrastructure and compute capacity.
The press covers each as an isolated deal. The structural shift is that organizations discovering your next medicine increasingly look like technology companies that happen to work in biology.
When pharma's core asset shifts from molecules to compute, which assumptions about healthcare competition still hold?
'Synthetic Minds' continues to reflect the synthetic forces reshaping our world. Quick, curated insights to feed your quest for a better understanding of our evolving synthetic future, powered by Futurwise:
1. Scientists at UC San Francisco have developed a method to directly reprogram T cells inside the body. This approach could eliminate barriers to access for thousands of patients. (UCSF)
2. In a breakthrough discovery, scientists have found a potential weakness in antibiotic-resistant bacteria, including Acinetobacter baumannii, and developed antibodies to target it. (LiveScience)
3. Amazon Web Services expands its healthcare footprint with the launch of Amazon Connect Health, an AI agent platform designed to streamline administrative tasks such as appointment scheduling, documentation, and patient verification. (TechCrunch)
4. Quantum computing has entered a new phase of practical application, as a joint effort between Cleveland Clinic and IBM demonstrates a hybrid workflow that models the electronic structure of a 303‑atom protein, changing pharmaceutical research. (Quantum Insider)
5. Mount Sinai Health System is taking a significant step forward in healthcare innovation by rolling out OpenEvidence, an AI-powered medical search and clinical decision-support platform. (HIT Consultant)
If you are interested in more insights, grab my latest, award-winning, book Now What? How to Ride the Tsunami of Change and learn how to embrace a mindset that can deal with exponential change.
If this newsletter was forwarded to you, you can sign up here.
Thank you.
Mark
